ARCT
Income statement / Annual
Last year (2025), Arcturus Therapeutics Holdings Inc's total revenue was $67.22 M,
a decrease of 51.43% from the previous year.
In 2025, Arcturus Therapeutics Holdings Inc's net income was -$65.78 M.
See Arcturus Therapeutics Holdings Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$67.22 M |
$138.39 M |
$157.75 M |
$205.76 M |
$12.36 M |
$9.54 M |
$20.79 M |
$15.75 M |
$13.00 M |
$20.38 M |
| Cost of Revenue |
$3.03 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$55.95 M
|
$0.00
|
$16.98 M
|
$410.00 K
|
$294.00 K
|
| Gross Profit |
$64.20 M
|
$138.39 M
|
$157.75 M
|
$205.76 M
|
$12.36 M
|
-$46.41 M
|
$20.79 M
|
-$1.23 M
|
$12.59 M
|
$20.09 M
|
| Gross Profit Ratio |
0.95
|
1
|
1
|
1
|
1
|
-4.86
|
1
|
-0.08
|
0.97
|
0.99
|
| Research and Development Expenses |
$112.21 M
|
$195.16 M
|
$192.13 M
|
$147.75 M
|
$173.76 M
|
$57.85 M
|
$33.64 M
|
$16.98 M
|
$15.92 M
|
$18.39 M
|
| General & Administrative Expenses |
$46.08 M
|
$52.82 M
|
$52.87 M
|
$46.07 M
|
$41.45 M
|
$23.22 M
|
$12.66 M
|
$20.58 M
|
$7.57 M
|
$5.36 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.90 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$46.08 M
|
$52.82 M
|
$52.87 M
|
$46.07 M
|
$41.45 M
|
$25.12 M
|
$12.66 M
|
$20.58 M
|
$7.57 M
|
$5.36 M
|
| Other Expenses |
-$19.14 M
|
-$13.92 M
|
-$9.05 M
|
-$244.00 K
|
$0.00
|
-$57.85 M
|
$0.00
|
$0.00
|
-$348.00 K
|
$1.42 M
|
| Operating Expenses |
$139.15 M
|
$234.06 M
|
$235.95 M
|
$193.58 M
|
$215.21 M
|
$25.12 M
|
$46.30 M
|
$37.56 M
|
$23.49 M
|
$25.17 M
|
| Cost And Expenses |
$142.18 M
|
$234.06 M
|
$235.95 M
|
$193.58 M
|
$215.21 M
|
$81.06 M
|
$46.30 M
|
$37.56 M
|
$23.49 M
|
$25.17 M
|
| Interest Income |
$10.10 M
|
$15.20 M
|
$17.36 M
|
$2.58 M
|
$753.00 K
|
$470.00 K
|
$408.00 K
|
$514.00 K
|
$89.00 K
|
$9.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$767.00 K
|
$3.00 M
|
$2.67 M
|
$831.00 K
|
$854.00 K
|
$186.00 K
|
$150.00 K
|
$295.00 K
|
| Depreciation & Amortization |
$3.03 M
|
$3.54 M
|
$2.96 M
|
$1.53 M
|
$1.19 M
|
$882.00 K
|
$684.00 K
|
$582.00 K
|
$410.00 K
|
$294.00 K
|
| EBITDA |
-$71.93 M |
-$77.40 M |
-$24.17 M |
$13.70 M |
-$201.66 M |
-$70.64 M |
-$24.45 M |
-$20.72 M |
-$10.34 M |
-$947.00 K |
| EBITDA Ratio |
-1.07
|
-0.56
|
-0.15
|
0.07
|
-16.32
|
-7.41
|
-1.18
|
-1.31
|
-0.8
|
-0.05
|
| Operating Income Ratio |
-1.12
|
-0.69
|
-0.5
|
0.06
|
-16.41
|
-7.5
|
-1.23
|
-1.38
|
-0.81
|
-1.23
|
| Total Other Income/Expenses Net |
$9.17 M
|
$14.72 M
|
$50.32 M
|
-$1.53 M
|
-$822.00 K
|
-$624.00 K
|
-$478.00 K
|
$26.00 K
|
-$409.00 K
|
-$536.00 K
|
| Income Before Tax |
-$65.78 M
|
-$80.95 M
|
-$27.89 M
|
$10.64 M
|
-$203.67 M
|
-$72.15 M
|
-$25.99 M
|
-$21.79 M
|
-$10.90 M
|
-$24.53 M
|
| Income Before Tax Ratio |
-0.98
|
-0.58
|
-0.18
|
0.05
|
-16.48
|
-7.56
|
-1.25
|
-1.38
|
-0.84
|
-1.2
|
| Income Tax Expense |
$0.00
|
-$4.00 K
|
$1.84 M
|
$1.30 M
|
$0.00
|
$0.00
|
$0.00
|
$212.00 K
|
$1.00 K
|
$73.00 K
|
| Net Income |
-$65.78 M
|
-$80.94 M
|
-$29.73 M
|
$9.35 M
|
-$203.67 M
|
-$72.15 M
|
-$25.99 M
|
-$21.79 M
|
-$10.90 M
|
-$24.60 M
|
| Net Income Ratio |
-0.98
|
-0.58
|
-0.19
|
0.05
|
-16.48
|
-7.56
|
-1.25
|
-1.38
|
-0.84
|
-1.21
|
| EPS |
-2.4 |
-3 |
-1.12 |
0.35 |
-7.74 |
-3.55 |
-2.13 |
-2.16 |
-3.53 |
-6.25 |
| EPS Diluted |
-2.4 |
-3 |
-1.12 |
0.35 |
-7.74 |
-3.55 |
-2.13 |
-2.16 |
-3.53 |
-6.25 |
| Weighted Average Shares Out |
$27.39 M
|
$27.00 M
|
$26.63 M
|
$26.45 M
|
$26.32 M
|
$20.31 M
|
$12.07 M
|
$10.07 M
|
$3.09 M
|
$3.94 M
|
| Weighted Average Shares Out Diluted |
$27.39 M
|
$27.00 M
|
$26.63 M
|
$27.09 M
|
$26.32 M
|
$20.31 M
|
$12.07 M
|
$10.07 M
|
$3.09 M
|
$3.94 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
